- Home
- AQST vs YAAS Comparison
AQST vs YAAS Comparison
Compare AQST & YAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- YAAS
- Stock Information
- Founded
- AQST 2004
- YAAS 2018
- Country
- AQST United States
- YAAS China
- Employees
- AQST N/A
- YAAS N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- YAAS Computer Software: Prepackaged Software
- Sector
- AQST Health Care
- YAAS Technology
- Exchange
- AQST Nasdaq
- YAAS Nasdaq
- Market Cap
- AQST 285.4M
- YAAS 265.0M
- IPO Year
- AQST 2018
- YAAS 2024
- Fundamental
- Price
- AQST $3.10
- YAAS $3.67
- Analyst Decision
- AQST Strong Buy
- YAAS
- Analyst Count
- AQST 8
- YAAS 0
- Target Price
- AQST $10.38
- YAAS N/A
- AVG Volume (30 Days)
- AQST 1.5M
- YAAS 107.7K
- Earning Date
- AQST 03-04-2025
- YAAS 01-01-0001
- Dividend Yield
- AQST N/A
- YAAS N/A
- EPS Growth
- AQST N/A
- YAAS N/A
- EPS
- AQST N/A
- YAAS N/A
- Revenue
- AQST $58,900,000.00
- YAAS $774,333.00
- Revenue This Year
- AQST $18.44
- YAAS N/A
- Revenue Next Year
- AQST N/A
- YAAS N/A
- P/E Ratio
- AQST N/A
- YAAS N/A
- Revenue Growth
- AQST 22.56
- YAAS N/A
- 52 Week Low
- AQST $2.24
- YAAS $3.20
- 52 Week High
- AQST $6.23
- YAAS $4.50
- Technical
- Relative Strength Index (RSI)
- AQST 34.77
- YAAS N/A
- Support Level
- AQST $2.96
- YAAS N/A
- Resistance Level
- AQST $3.30
- YAAS N/A
- Average True Range (ATR)
- AQST 0.21
- YAAS 0.00
- MACD
- AQST 0.01
- YAAS 0.00
- Stochastic Oscillator
- AQST 16.87
- YAAS 0.00
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.